Maia Biotechnology

Maia Biotechnology Dividend

Dividend of Maia Biotechnology (MAIA) as of Nov 10, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Maia Biotechnology 2026 pay?

According to the latest status from November 2026, Maia Biotechnology paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Maia Biotechnology price of 1.09 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Maia Biotechnology Dividends

Historical Maia Biotechnology Dividends
PaydateDividend

The Maia Biotechnology Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
The Maia Biotechnology Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the Maia Biotechnology Dividend Safe?

Maia Biotechnology has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Maia Biotechnology's Dividend Distributions

Maia Biotechnology’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Maia Biotechnology's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Maia Biotechnology's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Maia Biotechnology’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Maia Biotechnology Stock analysis

What does Maia Biotechnology do? MAIA Biotechnology, Inc. generates revenue through the development and commercialization of oncology drug candidates, focusing on targeted immuno-oncology therapies for difficult-to-treat cancers. The company's pipeline includes THIO (6-thio-dG, 6-thio-2’-deoxyguanosine), a telomere-targeting agent in Phase II clinical development for Non-Small Cell Lung Cancer, and Libtayo for advanced non-small-cell lung cancer treatment. MAIA is advancing a second-generation program with five compounds designed to improve specificity towards cancer cells and increase anticancer activity. The firm targets pharmaceutical companies and healthcare providers seeking innovative cancer treatments. The company's primary products are THIO and Libtayo, with THIO being a potentially first-in-class small molecule. MAIA is developing these therapies to improve and extend the lives of cancer patients, focusing on non-small-cell lung cancer and other difficult-to-treat cancers. The firm's second-generation pipeline aims to discover new compounds with enhanced properties compared to existing therapies. MAIA's clinical-stage approach allows it to partner with pharmaceutical entities for development and commercialization. MAIA Biotechnology's revenue model relies on the progression of its clinical-stage therapies through development phases, with potential partnerships and licensing agreements for commercialization. The company's focus on telomere-targeting agents like THIO positions it in the oncology drug development market. MAIA's pipeline includes Phase II studies for THIO in Non-Small Cell Lung Cancer, indicating near-term potential for partnerships or sales. The firm targets healthcare providers and pharmaceutical companies as key segments for its therapies. Maia Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Maia Biotechnology stock

Maia Biotechnology paid dividends every year for the past 0 years.

Maia Biotechnology is assigned to the 'Health' sector.

The dividends of Maia Biotechnology are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

All Key Metrics — Maia Biotechnology